Injection molder and contract manufacturer Tech Group is relocating
its Grand Rapids plant to a new molding facility in nearby Walker,
Michigan, which will be expanded to cope with the high demand for
medical devices and components.
Indian biopharmaceutical company Wockhardt has signed a deal with
Maharashtra Industrial Development Corporation (MIDC) to establish
a special economic zone (SEZ) in Aurangabad, India, in order to
expand its manufacturing capabilities.
Following numerous manufacturing failures, Discovery Laboratories
believes it has resolved the stability issues that have plagued
Surfaxin, its experimental respiratory treatment for infants, and
is now seeking a meeting with the...
Drug developing services provider Aptuit has acquired the
pharmaceutical services division of technology firm EaglePicher,
enriching its active pharmaceutical ingredient (API) and drug
substance manufacturing offerings.
Ferro Pfanstiehl Laboratories has commissioned a new validated
current good manufacturing practice (cGMP) supercritical
fluid-based particle engineering pilot facility, offering sizing,
purification and formulation services to its...
Bentley Pharmaceuticals has announced it will use the North
Carolina facilities of US-based services provider Cardinal Health
for the scale-up and manufacture of the clinical supplies of its
new intranasal insulin product.
Cardinal Health has been given the green light from the US Food and
Drug Administration (FDA) to start manufacturing the first
commercial drug at its new sterile facility in North Carolina.
Kemwell has sealed the deal on the purchase of Pfizer's Swedish
manufacturing plant and at the same time secured a long-term
contract manufacturing agreement with the drug giant.
Successful technology transfer and effective management can help
avoid disappointment with contract manufacturing arrangements,
which often fail to live up to pharmaceutical company expectations.
Wyeth has entered into a global agreement that allows it to use
Intracell's synthetic adjuvant IC31 in the formulation of five of
its investigational vaccines, aiming to simply mix it with antigens
without the need for conjugation.
A good selection process, with a realistic set of selection
criteria is essential when looking for the right contract
manufacturing partner, according to a new Datamonitor report.
Offshoring contract manufacturing is not the only option for large
pharma firms looking to drive productivity and efficiency gains in
drug manufacturing, warns a new report from independent market
analyst Datamonitor.
After selling a manufacturing plant in Texas to Cardinal Health two
years ago, Adams Respiratory Therapeutics has reacquired the
facility in order to produce its expectorant Mucinex (guaifenesin
extended-release), responding to a...
Canadian contract manufacturer Patheon has teamed up with specialty
pharmaceutical firm Depomed to offer its clients a controlled
release formulation which can grant their drugs increased
bioavailability and less frequent dosing.
Despite its consolidation, the competitive consumable sector still
offers potential for rapid growth and better profits in the
biopharmaceutical industry, while contract bioprocessing services
will be increasingly in demand, according...
For the first time Merck has opened the doors of its
under-construction manufacturing plant in North Carolina to public
officials, boasting it will eventually contribute about two-thirds
of its annual live-virus vaccine production.
India's potential to further boost its already dominant role in
global generics production, as well as an offshore location of
choice for contract manufacturing, presents an opportunity worth an
estimated $48bn (€38bn) in 2007,...
More problems at Patheon's Puerto Rican production facilities in
the third quarter of 2006 are expected to reduce the contract
manufacturer's earnings before interest, tax, depreciation and
amortisation (EBITDA) by more...
West Pharmaceutical Services has reported a huge surge in both
sales and profits for its second quarter, spurred on by the
increasing demand for injectable drugs as well as the lucrative
Exubera manufacturing contract, which helped...
Pharmaceutical excipients can have a profound impact on the release
profile of drugs, driving fine chemical companies to raise their
game since they realise their clients see excipients as more than
inactive ingredients.
More and more drugmakers are turning to health care companies not
just for their drug delivery technologies but also for their
regulatory and manufacturing expertise, asking them to take their
product from early stages all the way...
The Japanese pharmaceutical industry is eyeing India as a new hub
to conduct its contract manufacturing and clinical trials - India
is thirsty for new Japanese investment.
After launching its flagship oral insulin spray in Ecuador last
December, Generex is finally gearing up to take on big pharma in
the global non-injectable insulin arena and has picked Cardinal
Health to help meet manufacturing demands.
Cardinal Health has taken the contract manufacturing crown after
being honoured with a prestigious award from Frost & Sullivan
in recognition of its ability to provide biopharma firms with a
high quality service, while still remaining...
Cardinal Health has implemented a series of business reshuffles and
cost cutting measures in the hope of pulling itself out of poor
profitability after disappointing third quarter results.
Promed is due to start operations at its new research centre in
India, New Deli, this month, in a move that will bring the company
closer to becoming a global provider of drug development and supply
services.
Having inked two new deals with large Indian contract research
organisations (CROs), US generics major Taro Pharmaceutical
Industries is beginning to shift some of its product R&D to
India in a bid to enhance its competitive position...
Oman Pharmaceutical Products (OPP) has entered its first
outsourcing partnership in Europe with Finnish company
Dragenopharm, providing the first step in its strategy to offer
contract manufacturing services globally.
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...
